Adverse Effects of Intravenous Acetazolamide Administration for Evaluation of Cerebrovascular Reactivity Using Brain Perfusion Single-Photon Emission Computed Tomography in Patients With Major Cerebral Artery Steno-occlusive Diseases
-
- SAITO Hideo
- Department of Neurosurgery, Iwate Medical University
-
- OGASAWARA Kuniaki
- Department of Neurosurgery, Iwate Medical University
-
- SUZUKI Taro
- Department of Neurosurgery, Iwate Medical University
-
- KURODA Hiroki
- Department of Neurosurgery, Iwate Medical University
-
- KOBAYASHI Masakazu
- Department of Neurosurgery, Iwate Medical University
-
- YOSHIDA Kenji
- Department of Neurosurgery, Iwate Medical University
-
- KUBO Yoshitaka
- Department of Neurosurgery, Iwate Medical University
-
- OGAWA Akira
- Department of Neurosurgery, Iwate Medical University
この論文をさがす
抄録
Adverse effects of intravenous acetazolamide administration for evaluation of cerebrovascular reactivity using brain perfusion single-photon emission computed tomography (SPECT) were prospectively investigated in 100 patients with major cerebral artery, atherosclerotic, and steno-occlusive diseases. All patients underwent two SPECT studies (with and without acetazolamide challenge) at an interval of 2 or 3 days, received a questionnaire immediately after each SPECT study, and returned the answered questionnaire within 7 days after the study. None of the 100 patients studied experienced any symptoms during the SPECT study without acetazolamide challenge. Sixty-three patients (63%) developed symptoms during the SPECT study with acetazolamide challenge, such as headache, nausea, dizziness, tinnitus, numbness of the extremities, motor weakness of the extremities, and general malaise 1-3 hours (mean 1.6 hours) after administration of acetazolamide, and these symptoms lasted for 0.5-72 hours (mean 7.9 hours). Multivariate statistical analysis revealed that younger age (95% confidence interval [CI] 0.896-0.980, p = 0.0047) and female sex (95% CI 1.178-16.129, p = 0.0274) were significantly associated with development of symptoms with acetazolamide challenge. The incidences of the development of symptoms with acetazolamide challenge were 91% (21/23) and 41% (12/29) in subgroups of women <70 years and men ≥70 years, respectively. Patients should be informed of such adverse effects of intravenous acetazolamide administration prior to the acetazolamide challenge test for evaluation of cerebrovascular reactivity.<br>
収録刊行物
-
- Neurologia medico-chirurgica
-
Neurologia medico-chirurgica 51 (7), 479-483, 2011
一般社団法人 日本脳神経外科学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001205057000192
-
- NII論文ID
- 10029138411
-
- NII書誌ID
- AN00358613
-
- COI
- 1:STN:280:DC%2BC3MjgslGmsg%3D%3D
-
- ISSN
- 13498029
- 04708105
-
- PubMed
- 21785240
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- Crossref
- PubMed
- CiNii Articles
- KAKEN
-
- 抄録ライセンスフラグ
- 使用不可